Lingling Zhu Yanyang Liu Honglin Gao Jiewei Liu Qinghua Zhou Feng Luo
10.3389/fcell.2021.755135
Front Cell Dev Biol
2022 Jan 10;9:755135.
egfr exon 20 mutation histological transformation immune checkpoint blockade immune therapy non-small cell lung cancer
CC BY
https://pubmed.ncbi.nlm.nih.gov/35083213/
Case Reports
PMC8784849
35083213
Case Report: Partial Response Following Nivolumab Plus Docetaxel in a Patient With EGFR Exon 20 Deletion/Insertion (p.N771delinsGF) Mutant Lung Adenocarcinoma Transdifferentiated From Squamous Cell Carcinoma
2022